Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology

• Status: Withdrawn
• Trial end date: 2016-03-25
• Target enrollment: 0
• Participant gender: All

Summary

The investigators plan to use an herbal eye drop, Euphrasia, aka Eyebright, for post-operative inflammation for Peripheral Laser Iridotomy for the treatment of narrow angle glaucoma. A peripheral Laser Iridotomy is a simple laser procedure with few complications if the patient follows the post-operative instructions. In this procedure, a blue-green Argon laser is used to create an orifice in the iris to open the angle by allowing the aqueous from behind the iris to enter the anterior chamber. Rarely the procedure needs to be repeated. The main complications from this surgery are postoperative inflammation, bleeding, and postoperative pressure spikes.

The investigators will be using Weleda's Euphrasia D3 eye drops. The investigators plan to do a double blinded randomized control trial to objectively measure ocular inflammation in the same process that was used for the steroid eye drops that are currently out on the market. Some patients will be receiving steroids, prednisolone acetate, others, the herbal eye drop.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Larkin Community Hospital
• Collaborator: Nova Southeastern University
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Patients undergoing Peripheral Laser Iridotomy

Exclusion Criteria:

• Patients who have had an allergic reaction to Euphrasia (this will be asked to the patient at time of )

• Patients who have had an adverse reaction to steroids (obtained by chart review to determine safety of drop use)

• Patients who have inflammation before the LPI (Noted by seeing cell in the anterior chamber)

• Patients who had any complications during their cataract surgery (obtained by chart review to determine safety of procedure)

• Patients in whom more than 1500mW of energy was used during the Peripheral Laser Iridotomy

• Patients in whom the laser was used more than 130 times during the Peripheral Laser Iridotomy